Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Sep 30, 2025 | (Q1)Jun 30, 2025 | (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (Q2)Sep 30, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 78.32%-1.95K | -87.76%-1.64K | 50.10%-28.63K | -111.93%-21.64K | 101.29%2.87K | 25.43%-8.98K | 76.98%-874 | -188.19%-57.37K | 1,245.47%181.29K | -1,530.60%-222.82K |
| Net income from continuing operations | 119.99%4.94K | 70.49%-1.14K | 76.88%-41.86K | 86.06%-20.81K | 141.83%7.5K | -52.18%-24.69K | -261.34%-3.86K | -175.50%-181.01K | -287.94%-149.25K | -1,242.51%-17.93K |
| Asset impairment expenditure | 2,755.00%571 | 137.12%1.78K | --0 | -100.60%-769 | --0 | --20 | --749 | 662.82%132.56K | 642.60%129.04K | --3.51K |
| Unrealized gains and losses of investment securities | -3,513.03%-16.76K | -134.60%-673 | -52.05%4.62K | -57.75%821 | -52.80%1.36K | -93.90%491 | 159.98%1.95K | -3.68%9.64K | 9.53%1.94K | 145.53%2.89K |
| Change In working capital | -38.77%9.3K | -657.64%-1.61K | 146.40%8.61K | -100.44%-878 | 97.16%-6K | 492.76%15.2K | 109.78%288 | -200.78%-18.56K | 5,611.42%199.56K | -2,277.90%-211.3K |
| -Change in receivables | -394.56%-10.02K | -35.09%-154 | 110.97%624 | -250.93%-2.08K | -49.36%-581 | 174.07%3.4K | 1.72%-114 | -156.54%-5.69K | -201.02%-593 | -270.48%-389 |
| -Change in prepaid assets | ---- | ---- | --0 | --0 | --0 | ---- | ---- | -121.18%-186 | --0 | ---- |
| -Change in payables and accrued expense | 81.26%21.38K | -461.19%-1.45K | 162.97%7.99K | -99.40%1.2K | 97.43%-5.42K | 1,536.06%11.8K | 114.21%402 | -269.68%-12.68K | 6,785.10%200.15K | -2,081.64%-210.73K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 78.32%-1.95K | -87.76%-1.64K | 50.10%-28.63K | -111.93%-21.64K | 101.29%2.87K | 25.43%-8.98K | 76.98%-874 | -188.19%-57.37K | 1,245.47%181.29K | -1,530.60%-222.82K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 42.77%-114.28K | 50.95%-97.83K | -640.44%-16.45K | -412.50%-199.7K | -385.25%-199.46K | 161.87%3.04K | ||||
| Capital expenditure reported | ---- | ---- | 42.77%-114.28K | ---- | ---- | ---- | ---- | -3,558.25%-199.7K | ---- | ---- |
| Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | ---- | ---- | 42.77%-114.28K | 50.95%-97.83K | -640.44%-16.45K | ---- | ---- | -412.50%-199.7K | -385.25%-199.46K | 161.87%3.04K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 0 | 748.93%297.13K | -2.88K | |||||
| Net common stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 757.14%300K | --0 | ---- |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---2.88K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | ---- | ---- | --0 | --0 | --0 | ---- | ---- | 748.93%297.13K | ---2.88K | ---- |
| Net cash flow | ||||||||||
| Beginning cash position | -78.13%40.23K | -77.34%41.87K | 27.67%184.78K | -21.61%161.34K | 39.27%174.92K | 30.49%183.9K | 27.67%184.78K | 120.18%144.73K | 127.10%205.82K | 15.00%125.6K |
| Current changes in cash | 2,739.83%237.16K | -87.76%-1.64K | -456.84%-142.91K | -467.71%-119.47K | -116.93%-13.58K | 41.40%-8.98K | 76.98%-874 | -49.30%40.05K | -138.90%-21.04K | 531.65%80.22K |
| End cash Position | 58.58%277.39K | -78.13%40.23K | -77.34%41.87K | -77.34%41.87K | -21.61%161.34K | 39.27%174.92K | 30.49%183.9K | 27.67%184.78K | 27.67%184.78K | 127.10%205.82K |
| Free cash from | -98.55%-17.84K | -87.76%-1.64K | 44.41%-142.91K | -638.29%-135.92K | 101.31%2.87K | 41.40%-8.98K | 76.98%-874 | -913.43%-257.08K | 13.51%-18.41K | -1,647.21%-219.54K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.